Biohaven | ApexOnco - Clinical Trials news and analysis

x

“It's very intuitive and always up-to-date”

Monika Vogelmann

Head of Market Insights Oncology Europe

Daiichi Sankyo

Click here for more information

Interviews

6 December 2024

Biohaven aims to become an oncology fast follower

The group’s cancer focus is a TROP2 ADC it reckons could have a safety and efficacy edge.

Subscribe to Biohaven